Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug, GS-0415, help keep HIV in check? a First-in-Human trial aims to find out

NCT ID NCT07719491

Not yet recruiting Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called GS-0415 in people with HIV who already have the virus well-controlled by standard antiretroviral therapy. The study will give single and multiple doses of GS-0415 to evaluate its safety, tolerability, and how the body processes the drug. The goal is to gather initial data to see if GS-0415 could become a new treatment option for HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called GS-0415
What this could lead to
If safe and effective, GS-0415 could offer a new option for controlling HIV in people already on suppressive therapy.
What could go wrong
This is an early, first-in-human trial focused on safety and dosing, not on efficacy. The drug may not work as hoped or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV -1 INFECTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.